Z-L-Ala^P(OMe)-OH | 121843-86-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Z-L-Ala^P(OMe)-OH
• 英文别名: (R)-benzyl 1-(monomethoxyphosphoryl)ethylcarbamate；(R)-1-(benzyloxycarbonylamino)ethylphophonic acid monomethyl ester；methoxy-[(1R)-1-(phenylmethoxycarbonylamino)ethyl]phosphinic acid
• CAS: 121843-86-5
• 化学式: C₁₁H₁₆NO₅P
• 分子量: 273.226
• InChiKey: LKFYLGJTOQMUQN-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Z-L-Ala^P(OMe)-OH 在 氯化亚砜 作用下， 以 四氯化碳 为溶剂， 反应 1.5h， 生成 Z-L-Ala^P(OMe)-Cl
  参考文献：
  名称：

  Synthesis ofα-Aminophosphonic Octapeptide, Phe–Gly–Ser–Leu–Ala^P–Phl–Leu–Pro, an Analog with Partial Sequence oferbB-2 Gene Product

  摘要：

  对具有膦酸酯键的八肽进行了化学合成，其对应于erb B-2基因产物的部分序列的变体。通过羟基肽的镁盐与膦酰氯的偶联反应成功制备了膦酸酯键，且未破坏肽键。作为最终产物的游离氨基膦肽在ODS柱上显示出单峰，并且组分氨基酸的比例合理。这里采用的反应系列可能可用作制备膦酸肽的一般程序。

  DOI：

  10.1246/bcsj.68.942
• 作为产物：
  描述：

  dimethyl (L-1-benzoyloxycarbonylamino)ethylphosphonate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 Z-L-Ala^P(OMe)-OH
  参考文献：
  名称：

  An easy entry to optically active α-amino phosphonic acid derivatives using phase-transfer catalysis (PTC)

  摘要：

  在不对称亲水磷腈反应中空前绝后地使用相转移催化（PTC），使得直接从α-酰胺砜获得一系列光学活性的α-氨基膦酸衍生物成为可能。

  DOI：

  10.1039/b807027j

文献信息

• Phosphonic acid derivative having inhibitory activity against carboxypeptidase B
  申请人：Meiji Seika Kaisha Ltd.

  公开号：US20030119787A1

  公开（公告）日：2003-06-26

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: 1 wherein R 1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R 2 and R 3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH 2 —, —O—, or —NH—; A represents the following group (II): 2 [in which R 7 and R 8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R 9 and R 10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  以下是通用式（I）及其药学上可接受的盐所代表的化合物：其中R1代表氢原子、烷基、取代烷基等；R2和R3代表氢原子、烷基、取代烷基、烷氧基等；X代表—CH2—、—O—或—NH—；A代表以下基团（II）：其中R7和R8代表氢原子、烷基、酰基、烷氧羰基等；R9和R10代表氢原子、卤素原子、羟基、苯基、烷基等；E代表氢原子等，具有对羧肽酶B的抑制活性，可用于治疗和/或预防血栓性疾病。
• Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
  申请人：Meiji Seika Kaisha Ltd.

  公开号：US06576627B1

  公开（公告）日：2003-06-10

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2 and R3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH2—, —O—, or —NH—; A represents the following group (II): [in which R7 and R8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9 and R10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  以下是通式（I）及其药学上可接受的盐所代表的化合物： 其中，R1代表氢原子，烷基，取代烷基等；R2和R3代表氢原子，烷基，取代烷基，烷氧基等；X代表—CH2—、—O—或—NH—；A代表以下基团（II）： 【其中，R7和R8代表氢原子，烷基，酰基，烷氧羰基等；R9和R10代表氢原子，卤素原子，羟基，苯基，烷基等等；E代表氢原子等，具有对羧肽酶B的抑制活性，可用于治疗和/或预防血栓性疾病。】
• PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1152004A1

  公开（公告）日：2001-11-07

  A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2 and R3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents -CH2-, -O-, or -NH-; A represents the following group (II): [in which R7 and R8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9 and R10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.

  由以下通式（I）代表的化合物及其药理学上可接受的盐： 其中 R1 代表氢原子、烷基、取代的烷基等；R2 和 R3 代表氢原子、烷基、取代的烷基、烷氧基等；X 代表 -CH2-、-O- 或 -NH-；A 代表以下基团 (II)： [其中 R7 和 R8 代表氢原子、烷基、酰基、烷氧基羰基等；R9 和 R10 代表氢原子、卤素原子、羟基、苯基、烷基等]等；E 代表氢原子等，对羧肽酶 B 具有抑制活性，可用于血栓性疾病的治疗和/或预防。
• Phosphonate Ester Synthesis Using a Modified Mitsunobu Condensation
  作者：David A. Campbell、Jason C. Bermak

  DOI：10.1021/jo00082a027

  日期：1994.2
• Phosphonic acid derivatives having carboxypeptidase B inhibitory action
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1152004B1

  公开（公告）日：2003-05-07